Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OM 
Outset Medical Inc (OM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: OM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $25.75
1 Year Target Price $25.75
| 3 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 31.83% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 248.02M USD | Price to earnings Ratio - | 1Y Target Price 25.75 |
Price to earnings Ratio - | 1Y Target Price 25.75 | ||
Volume (30-day avg) 5 | Beta 2.14 | 52 Weeks Range 5.85 - 25.35 | Updated Date 08/29/2025 |
52 Weeks Range 5.85 - 25.35 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -18.75 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.2382 | Actual -1.04 |
Profitability
Profit Margin -82.06% | Operating Margin (TTM) -53.68% |
Management Effectiveness
Return on Assets (TTM) -15.79% | Return on Equity (TTM) -87.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 166197054 | Price to Sales(TTM) 2.08 |
Enterprise Value 166197054 | Price to Sales(TTM) 2.08 | ||
Enterprise Value to Revenue 1.39 | Enterprise Value to EBITDA -0.24 | Shares Outstanding 17766200 | Shares Floating 11274071 |
Shares Outstanding 17766200 | Shares Floating 11274071 | ||
Percent Insiders 2.67 | Percent Institutions 103.11 |
Upturn AI SWOT
Outset Medical Inc
Company Overview
History and Background
Outset Medical, Inc. was founded in 2011. It focuses on developing and commercializing innovative technologies to improve the dialysis experience. A key milestone was the development and commercialization of the Tablo Hemodialysis System.
Core Business Areas
- Tablo Hemodialysis System: This system allows for dialysis to be performed in a variety of settings, including hospitals, clinics, and at home. It offers a simplified user experience and integrated water purification.
- Dialysis Consumables and Services: Outset Medical provides related consumables and services necessary for the operation of the Tablo system.
Leadership and Structure
The leadership team includes Leslie Trigg (CEO), and Nabeel Ahmed (CFO). The company has a typical corporate structure with departments focused on R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- Tablo Hemodialysis System: A single, integrated system for hemodialysis treatment, offering improved ease of use and reduced infrastructure requirements. While precise market share figures are dynamic and difficult to pinpoint due to the evolving nature of the dialysis market, Tablo aims to capture a significant portion of the market moving toward home and simplified dialysis. Competitors include Fresenius Medical Care, DaVita, and Baxter International.
Market Dynamics
Industry Overview
The dialysis market is characterized by a growing prevalence of kidney disease, an aging population, and advancements in dialysis technology. The trend toward home hemodialysis is increasing.
Positioning
Outset Medical is positioned as an innovator in the dialysis market, offering a user-friendly and versatile system for both clinical and home settings. Their competitive advantage lies in the Tablo system's ease of use and integrated design.
Total Addressable Market (TAM)
The global dialysis market is estimated to be tens of billions of dollars. Outset is positioned to address a portion of this TAM by focusing on innovation and simplicity in its solutions.
Upturn SWOT Analysis
Strengths
- Innovative Tablo system
- Simplified user experience
- Integrated water purification
- Potential for home dialysis market growth
Weaknesses
- Limited market share compared to established players
- Reliance on a single primary product
- Scalability challenges in manufacturing and distribution
Opportunities
- Expanding home dialysis market
- Partnerships with healthcare providers
- Development of new dialysis technologies
- Geographic expansion
Threats
- Competition from established dialysis providers
- Regulatory changes affecting dialysis treatment
- Reimbursement pressures from insurance companies
- Technological obsolescence
Competitors and Market Share
Key Competitors
- FMS
- DVA
- BAX
Competitive Landscape
Outset Medicalu2019s Tablo system offers advantages in ease of use and integrated water purification. However, it competes against established dialysis providers with broader service offerings and existing infrastructure. Outset has a unique positioning based on simplification but limited Market Share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is dynamic. Refer to financial documentation for information.
Future Projections: Refer to analyst reports for forward-looking growth projections. Projections vary based on performance
Recent Initiatives: Recent initiatives include expansion of Tablo system deployment and partnerships with healthcare providers. Also, increasing efforts to expand the adoption of Tablo within the home dialysis market.
Summary
Outset Medical is an innovative company in the dialysis market with its Tablo system, offering a simplified dialysis experience. However, it faces significant competition from established players with larger market shares and broader service offerings. The company is focused on expanding its presence in the home dialysis market, but it needs to continue innovating and scaling its operations to compete effectively and manage costs. Reimbursement and regulatory changes are key external factors to watch.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is approximate and subject to change. Financial data should be independently verified.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Outset Medical Inc
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 2020-09-15 | President, CEO & Chairman Ms. Leslie L. Trigg | ||
Sector Healthcare | Industry Medical Devices | Full time employees 354 | Website https://www.outsetmedical.com |
Full time employees 354 | Website https://www.outsetmedical.com | ||
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.